4.7 Article

How I treat hemophagocytic lymphohistiocytosis

期刊

BLOOD
卷 118, 期 15, 页码 4041-4052

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-03-278127

关键词

-

资金

  1. National Institutes of Health [R01HL091769]
  2. American Society of Hematology
  3. Hoag Foundation

向作者/读者索取更多资源

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation, occurring as either a familial disorder or a sporadic condition, in association with a variety of triggers. This immune dysregulatory disorder is prominently associated with cytopenias and a unique combination of clinical signs and symptoms of extreme inflammation. Prompt initiation of immunochemotherapy is essential for survival, but timely diagnosis may be challenging because of the rarity of HLH, its variable presentation, and the time required to perform diagnostic testing. Therapy is complicated by dynamic clinical course, high risk of treatment-related morbidity, and disease recurrence. Here, we review the clinical manifestations and patterns of HLH and describe our approach to the diagnosis and therapy for this elusive and potentially lethal condition. (Blood. 2011; 118(15):4041-4052)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据